Clinical trial

The Influence of the "washoku" Diet on the Gut Microbiota in Postmenopausal Women

Recruiting now · Not applicable · 1 countries · Registry ID NCT06673199

Recruiting nowNot applicableInterventional

What this study is about

Menopause is a special period in a woman's life, when a sudden drop in estrogen levels leads to the cessation of menstrual cycles. Hormonal changes and a decreasing metabolic rate contribute to weight gain and the appearance of numerous metabolic disorders, such as dyslipidemia, impaired glucose tolerance, insulin resistance, hyperinsulinemia, and type 2 diabetes. Currently, effective and inexpensive dietary therapeutic solutions are being sought to improve the health of this group of women. It is suggested that the Japanese washoku diet, which includes products rich in isoflavones, fiber (soy products) and unsaturated omega-3 fatty acids (fish, seaweed), may be a good solution, as it contributes to the regulation of hormonal balance, lowering cholesterol levels, and reducing the risk of insulin resistance. Moreover, the composition of such a diet may also affect the diversity of the intestinal microbiota and the production of its metabolites, such as short-chain fatty acids, and thus contribute to the improvement of patients' health. Taking the above into account, the aim of the study will be to assess the effect of the Japanese washoku diet on the composition of the intestinal microbiota and its metabolites in a group of overweight or obese women after natural menopause. Specific objectives: * Assessment of anthropometric parameters (body weight, height, waist circumference, hip circumference) and body composition and bone density. * Assessment of parameters of carbohydrate metabolism (glucose, insulin concentration), lipid metabolism (total cholesterol (T-C), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), non-HDL cholesterol (non-HDL-C) and triglycerides). * Analysis of intestinal microbiota, short-chain fatty acids in the feces of women.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age45 Years to 65 Years
SexFemale
Healthy volunteersNot accepted
ConditionMenopause

Full registry criteria

Inclusion Criteria: * age 45 to 65, * at least one year after natural menopause, * BMI \> 25 kg/m2 * waist circumference \> 80 cm. Exclusion Criteria: * use of hormone replacement therapy; * taking antibiotics or probiotics in the last 6 months from the date of commencement of the scientific experiment, * taking medications regulating carbohydrate or lipid metabolism in the last 4 weeks from the date of commencement of the scientific experiment, * taking medications regulating body weight in the last 3 months from the date of commencement of the scientific experiment, * diseases of the thyroid gland, liver, heart, kidneys, digestive system, anemia, neoplastic diseases, * smoking or alcohol consumption in amounts exceeding 100 g/week.

Treatments and study arms

Washoku diet

Dietary Supplement

The Washoku diet will consist of following the principles of a healthy eating plate, which will be supplemented with elements of the Washoku diet (30g of roasted black soybeans and 5g of wakame). Food products will be given to women on the day of the first meeting. The Washoku diet will be used for 7 days a week for a period of 1 month (4 weeks).

Primary outcomes

Change in composition of the intestinal microbiotaWeek 0 (pre-intervention) and week 4 (post-intervention)

Participants will be asked to provide stool samples at each scheduled meeting. Detailed instructions on sample collection and transport will be provided by the people conducting the study, and participants will receive containers containing preservative liquid. Bacterial DNA will be isolated from the provided stool samples using the QIAmp Fast DNA Stool Mini Kit. Then, the DNA will be properly secured and sent to an external company, Genomed S.A. (Warsaw, Poland), in which the assessment of microbiota will be carried out by metagenomic 16s rRNA sequencing using the V3-V4 region. Then, a bioinformatics analysis will be performed in the R environment using packages such as phyloseq, vegan, microbiome.

Change in body weightWeek 0 (pre-intervention) and week 4 (post-intervention)

Body weight measurement in a standing position, without shoes, in light clothing, on an electronic scale with an accuracy of 0.1 kg.

Change in body compositionWeek 0 (pre-intervention), week 4, week 8 and week 12 (post-intervention)

Body composition will be measured using dual-energy X-ray absorptiometry (DXA) as a method that uses the phenomenon of weakening the beam of ionizing radiation passing through tissues of various densities. This method is safe and non-invasive. The mass of adipose tissue, including visceral fat tissue, the mass of lean tissue are measured. (expressed in the same unit - kilograms)

Change in circumferencesWeek 0 (pre-intervention) and week 4 (post-intervention)

Waist and hip measurements will be taken using an elastic tape. Waist circumference measurement - the tape is placed horizontally or slightly obliquely halfway between the lower edge of the ribs and the upper crest of the ilium. Measurement performed during apnea.

Change in lipid profileWeek 0 (pre-intervention) and week 4 (post-intervention)

Blood will be collected four times from the antecubital vein on an empty stomach, into test tubes with clotting granules (a single sample will amount to a total of 18 ml). The serum will be obtained by centrifugation of a venous blood clot. Total cholesterol (T-C), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and triglycerides concentrations will be determined by a certified external laboratory. The nonHDL-C parameter will be calculated using the formula: nonHDL-C = T-C - HDL-C. (expressed in the same unit - mg/dl or mmol/l).

Change in glucose metabolismWeek 0 (pre-intervention) and week 4 (post-intervention)

Blood will be collected four times from the antecubital vein on an empty stomach, into test tubes with clotting granules (a single sample will amount to a total of 18 ml). The serum will be obtained by centrifugation of a venous blood clot. Insulin concentration will be performed using the ELISA enzyme-linked immunosorbent assay, while glucose will be determined by a certified external laboratory. (expressed in the same unit - mg/dl or mmol/l).

Change in urinary isoflavone contentWeek 0 (pre-intervention) and week 4 (post-intervention)

Soy isoflavone concentrations will be assessed in a 24-hour urine sample provided by women before and after the study using high-performance liquid chromatography.

Change in urine pHWeek 0 (pre-intervention) and week 4 (post-intervention)

pH will be assessed in a 24-hour urine sample provided by women before and after the study using litmus paper or laboratory pH meter.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Poznań University of Life Sciences🇵🇱 Poznan, Wielkopolska, Poland
Joanna Bajerska, Assoc. Prof.Contact
Joanna M. Pieczyńska-Zając, M.Sc.Contact
Joanna M. Pieczyńska-Zając, M.Sc.Contact